Detalles de la búsqueda
1.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet;
390(10101): 1499-1510, 2017 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28750935
2.
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
Open Forum Infect Dis;
9(4): ofac067, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35350172
3.
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS;
36(2): 195-203, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652287
4.
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Open Forum Infect Dis;
8(9): ofab439, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34557563
Resultados
1 -
4
de 4
1
Próxima >
>>